CA-ZYNGA
8.4.2021 14:02:13 CEST | Business Wire | Press release
Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, today announced the worldwide launch of Puzzle Combat , a new mobile match-3 action role-playing game (RPG) where players recruit heroes, build bases and compete in player-vs-player (PvP) battles in a zombie-themed setting. Puzzle Combat is developed by Helsinki-based Small Giant Games , a subsidiary of Zynga Inc. and the studio behind the hit game Empires & Puzzles .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210408005009/en/
In Puzzle Combat , players will immerse themselves in battling enemies from the dangerous Dread Army with power-ups by creating unique match combinations. Players recruit spies, medics, demolition experts and more to fight on their side, each bringing unique special attacks to the fray. Players will also design impenetrable bases by constructing and upgrading buildings like foundries, workshops, training schools and quarters.
“Puzzle Combat gives players the rush of commanding the ultimate squad of heroes, all through the familiar fun of a match-3 experience,” said Jose Saarniniemi, Managing Director of Small Giant Games. “By combining key elements of Empires & Puzzles with a new, modern combat-themed game design, Puzzle Combat immerses players in a dynamic, action-packed virtual world filled with zombies. Following today’s release, we expect Puzzle Combat t o build a community of engaged gamers with additional themes and upgraded features designed to appeal to players around the world.”
Puzzle Combat matches players in PvP battles with other players around the world. To achieve combat dominance, players summon hundreds of individualized powerful heroes, each with unique abilities, and collect different weapons to upgrade and use in the field. As players progress, they can also join alliances to share best tactics and compete in challenging team events to promote their heroes, advance together and form the ultimate fighting force.
Key gaming highlights include:
- More than 200 unique heroes for players to collect and upgrade.
- Fast-paced match-3 action with special attacks unlocked by matching similar tiles in unique combinations.
- Base-building designed to train your recruits into heroes, farm for food, mine metals, craft critical battle items and more.
- Extensive PvP raid seasons with valuable rewards.
- Cooperative alliance game modes to dismantle powerful war machines, attack rivals in team battles and dominate in team events.
- Social features, such as global and alliance chats, allow players to exchange tactics and form teams to achieve the next level of gameplay.
- Limited time events to earn unique rewards and compete against other players.
Puzzle Combat is available now for iOS and Android as a free download.
For more information, visit:
Facebook
Twitter
Instagram
Zynga will release its first quarter 2021 results after the close of the market on Wednesday, May 5, 2021.
Editor’s Note:
To view the supporting assets for Puzzle Combat, please click here .
About Zynga Inc.
Zynga is a global leader in interactive entertainment with a mission to connect the world through games. To date, more than one billion people have played Zynga’s franchises including CSR Racing™ , Empires & Puzzles™ , Merge Dragons!™ , Merge Magic!™ , Toon Blast™ , Toy Blast™ , Words With Friends™ and Zynga Poker™ . Zynga’s games are available in more than 150 countries and are playable across social platforms and mobile devices worldwide. Founded in 2007, the company is headquartered in San Francisco with locations in the U.S., Canada, the U.K., Ireland, India, Turkey and Finland. For more information, visit www.zynga.com or follow Zynga on Twitter , Instagram , Facebook or the Zynga blog .
FORWARD-LOOKING STATEMENT
This press release contains forward-looking statements, relating to, among other things, our expectations related to the launch of Puzzle Combat , including its launch and reception, adoption by players, game features and highlights, and overall growth opportunities. Forward-looking statements often include words such as “will,” “planned,” “intends,” “anticipate,” “believe,” “target,” “expect,” and statements in the future tense are generally forward-looking. The achievement or success of the matters covered by such forward-looking statements involves significant risks, uncertainties, and assumptions. Undue reliance should not be placed on such forward-looking statements, which are based on information available to us on the date hereof. We assume no obligation to update such statements. More information about these risks, uncertainties, and assumptions is or will be described in greater detail in our public filings with the Securities and Exchange Commission (the “SEC”), copies of which may be obtained by visiting our Investor Relations website at http://investor.zynga.com or the SEC’s website at www.sec.gov .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210408005009/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 14:30:00 CET | Press release
Investment lead by OTB Ventures and Alpha Intelligence CapitalWaiv develops AI-powered precision testing to better identify and stratify patients in the clinic and in clinical trials, transforming patient careWaiv extends Owkin’s strategy of real-world validation for its AI Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and colla
RQM+ Launches SMART Solutions Life Cycle Partnership Model12.3.2026 14:30:00 CET | Press release
Helps MedTech Companies Navigate MDR, IVDR, and AI-Enabled Device Development RQM+, a leading MedTech CRO offering regulatory consulting, clinical trial, laboratory, and reimbursement services, today announced the launch of SMART Solutions, a life cycle partnership model designed to help medical device and diagnostics companies manage growing regulatory and development complexity. SMART Solutions introduces a strategy-led operating framework that unifies regulatory, quality, clinical, reimbursement, and laboratory expertise to support MedTech companies across the entire product life cycle to help reduce risk from early development through post-market. “MedTech companies are navigating unprecedented complexity as regulatory expectations evolve, product innovation accelerates, and post-market expectations are expanding,” said John Potthoff, Ph.D., chief executive officer of RQM+. “SMART Solutions moves beyond traditional consulting by providing an integrated life cycle partnership that h
Cryptio Raises $45m Series B as Digital Assets Move Into Regulated Financial Markets12.3.2026 14:06:00 CET | Press release
The system of record for tokenized finance – ERP infrastructure for institutions operating in digital assets Cryptio, a leader in financial data transformation and enterprise resource planning (ERP) applications for regulated digital assets, announced today a $45 million Series B funding round co-led by BlackFin Capital Partners and Sentinel Global, with participation from 1kx, Alven, BlueYard Capital and Ledger Cathay Capital. Banks, exchanges, asset managers, including Société Générale’s SG Forge, Circle, Gemini, and Securitize rely on Cryptio to ensure financial integrity across their digital assets businesses. Existing ERP systems fall short for digital assets Traditional ERP and accounting systems were not designed for blockchain-native assets, real-time reporting, or modern custody frameworks. As regulated financial institutions expand into stablecoins, tokenized securities and other on-chain instruments, these limitations create material operational and reporting challenges. Cry
HyperLight Introduces 145 GHz Reference Modulators to Enable 448Gbps per Lane Datacom and 260GBaud Telecom Development12.3.2026 14:03:00 CET | Press release
HyperLight Corporation, creator of the TFLN Chiplet™ platform, today announced the release of its 145 GHz Packaged Intensity Modulator (IM), expanding the company‘s high-speed modulator portfolio. The new device is designed for ultra-wide modulation bandwidth, high signal fidelity, and stable operation control, enabling 448 Gbps per lane intensity-modulated-direct-detection (IMDD), 260 GBaud coherent links, and broadband RF photonics systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312319685/en/ Fig. 1: HyperLight’s 145 GHz intensity modulator for 448Gbps per lane IMDD and 260GBaud coherent applications, with operational electro-optical bandwidth >145GHz, stable bias control, 0.8 mm-connector; available in O-, C-, and L-bands. As symbol rates and analog bandwidth requirements continue to rise across data center interconnects, AI-driven photonics infrastructure, and laboratory test environments, system architects in
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences12.3.2026 14:00:00 CET | Press release
Transaction deepens insights into Sec61 selectivity for targeted protein degradation, supporting accelerated development of Enodia’s novel small-molecule inhibitors Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, and Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Enodia has acquired Kezar’s assets from its Sec61-based discovery and development program. The acquisition enables Enodia to advance its understanding of Sec61 selectivity mechanisms, expanding biological and translational insights for faster progression toward key clinical milestones. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312627573/en/ Under the terms of the purchase agreement between Enodia and Kezar, Kezar w
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
